Cite
HARVARD Citation
Winer, I. et al. (n.d.). 347 Clinical outcomes of ovarian cancer patients treated with ALKS 4230, a novel engineered cytokine, in combination with pembrolizumab: ARTISTRY-1 trial. Journal for immunotherapy of cancer. pp. A211-A212. [Online].